Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 80403
Tytuł:
The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance.
Autorzy:
Liu A; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Gao Y; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Wang Q; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Lin W; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Ma Z; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Yang X; Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. .
Chen L; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. .
Xu D; Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Sep 19; Vol. 21 (1), pp. 641. Date of Electronic Publication: 2023 Sep 19.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Clonal Evolution*/genetics
Prostatic Neoplasms*/genetics
Humans ; Male ; Androgen Antagonists ; Androgens ; Tumor Microenvironment ; East Asian People ; Prostatic Neoplasms, Castration-Resistant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Autorzy:
Qi F; Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Xu Z; Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Electronic address: .
Zou Q; Department of Urologic Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2023 Mar; Vol. 83 (3), pp. e76-e77. Date of Electronic Publication: 2023 Jan 03.
Typ publikacji:
Letter; Comment
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Genes, BRCA1*
Genes, BRCA2*
Humans ; Male ; Abiraterone Acetate ; Indoles ; Mutation ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics
Opinia redakcyjna
Szczegóły
Tytuł:
CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer.
Autorzy:
Zhang N; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huang D; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ruan X; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ng AT; Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong, China; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Tsu JH; Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong, China; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Jiang G; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huang J; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhan Y; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Na R; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: .
Pokaż więcej
Źródło:
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy [Drug Resist Updat] 2023 Mar; Vol. 67, pp. 100912. Date of Electronic Publication: 2023 Jan 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Ubiquitin-Protein Ligases*/genetics
Humans ; Male ; ATPases Associated with Diverse Cellular Activities/genetics ; ATPases Associated with Diverse Cellular Activities/metabolism ; ATPases Associated with Diverse Cellular Activities/therapeutic use ; Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Clustered Regularly Interspaced Short Palindromic Repeats ; CRISPR-Cas Systems ; Early Detection of Cancer ; High-Throughput Screening Assays ; Neoplasm Grading ; Prostatic Neoplasms/genetics ; Proteomics ; Ubiquitins/genetics ; Ubiquitins/metabolism ; Ubiquitins/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Autorzy:
Loehr A; Translational Medicine, Clovis Oncology, Boulder, CO, USA.
Chowdhury S; Medical Oncology, Guy's Hospital, London, UK; Sarah Cannon Research Institute, London, UK.
Abida W; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: .
Pokaż więcej
Źródło:
European urology [Eur Urol] 2023 Mar; Vol. 83 (3), pp. e78. Date of Electronic Publication: 2023 Jan 07.
Typ publikacji:
Letter; Comment
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Humans ; Male ; Indoles ; Mutation ; Prostatic Neoplasms ; Genes, BRCA1 ; Genes, BRCA2
Opinia redakcyjna
Szczegóły
Tytuł:
MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis.
Autorzy:
Gan J; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Liu S; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Zhang Y; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
He L; Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Bai L; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Liao R; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Zhao J; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Guo M; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Jiang W; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Li J; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Li Q; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Mu G; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Wu Y; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Wang X; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Zhang X; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Zhou D; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Lv H; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Wang Z; Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Zhang Y; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Qian C; Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Feng M; Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Chen H; Department of Urologic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Meng Q; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Huang X; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China. .; NHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, Heilongjiang, 150081, China. .
Pokaż więcej
Źródło:
Experimental & molecular medicine [Exp Mol Med] 2022 Aug; Vol. 54 (8), pp. 1290-1305. Date of Electronic Publication: 2022 Aug 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
MicroRNAs*/genetics
MicroRNAs*/metabolism
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/therapy
Protein Tyrosine Phosphatase, Non-Receptor Type 4*/genetics
Protein Tyrosine Phosphatase, Non-Receptor Type 4*/metabolism
STAT3 Transcription Factor*/genetics
STAT3 Transcription Factor*/metabolism
Apoptosis/genetics ; Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mesenchymal Stem Cells/metabolism ; Phosphoric Monoester Hydrolases/genetics ; Phosphoric Monoester Hydrolases/metabolism ; Phosphoric Monoester Hydrolases/therapeutic use ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Autorzy:
Barata PC; Department of Hematology Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Leith A; Oncology, Adelphi Real World, Bollington, UK.
Ribbands A; Oncology, Adelphi Real World, Bollington, UK.
Montgomery R; Oncology, Adelphi Real World, Bollington, UK.
Last M; Formerly of Adelphi Real World, Bollington, UK.
Arondekar B; Global Value and Evidence, Pfizer Inc., Collegeville, PA, USA.
Ivanova J; Global Value and Evidence, Pfizer Inc., New York, NY, USA.
Niyazov A; Global Value and Evidence, Pfizer Inc., New York, NY, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2023 Sep 07; Vol. 28 (9), pp. 780-789.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Adult ; Humans ; Aged ; United States/epidemiology ; Androgen Antagonists/therapeutic use ; Medicare ; Taxoids/therapeutic use ; Castration ; Treatment Outcome
Czasopismo naukowe
Szczegóły
Tytuł:
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
Autorzy:
Barata PC; Department of Hematology Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Leith A; Department of Internal Medicine, Adelphi Real World, Bollington, UK.
Ribbands A; Department of Internal Medicine, Adelphi Real World, Bollington, UK.
Montgomery R; Department of Internal Medicine, Adelphi Real World, Bollington, UK.
Last M; Department of Internal Medicine, Formerly of Adelphi Real World, Bollington, UK.
Arondekar B; Global Value and Evidence, Oncology, Pfizer Inc., Collegeville, PA, USA.
Ivanova J; Global Value and Evidence, Oncology, Pfizer Inc., New York, NY, USA.
Niyazov A; Global Value and Evidence, Oncology, Pfizer Inc., New York, NY, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2023 Sep 07; Vol. 28 (9), pp. e737-e747.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Humans ; Docetaxel/therapeutic use ; Taxoids/therapeutic use ; Androgen Antagonists/therapeutic use ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Autorzy:
Ghamande SS; Medical College of Georgia, Augusta, GA, USA. Electronic address: .
Klaassen Z; Division of Urology, Department of Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Augusta, GA, USA. Electronic address: .
Wallis CJD; Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Canada; Division of Urology, Department of Surgery, University Health Network, Toronto, Canada.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2023 Sep; Vol. 84 (3), pp. 350-351. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Comment
MeSH Terms:
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Humans ; Male ; Androgen Antagonists/therapeutic use ; Androgens/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Docetaxel/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
American Indian/Alaska Native men are less likely to receive prostate-specific antigen testing and digital rectal exams from primary care providers than White men: a secondary analysis of the National Ambulatory Medical Care Survey from 2012-2018.
Autorzy:
Gillette C; Department of PA Studies, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC, 27157, USA. .; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA. .
Locklear T; Department of Public Health Education, School of Health and Human Sciences, University of North Carolina at Greensboro, Greensboro, NC, USA.
Bell R; Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Bates N; Department of PA Studies, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC, 27157, USA.
Ostermann J; Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Reuland D; Department of General Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Foley K; Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Lashmit C; High Point Family Practice, Atrium Health Wake Forest Baptist, High Point, NC, USA.
Crandall S; Department of PA Studies, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC, 27157, USA.
Pokaż więcej
Źródło:
Cancer causes & control : CCC [Cancer Causes Control] 2023 Sep; Vol. 34 (9), pp. 749-756. Date of Electronic Publication: 2023 May 23.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Physical Examination*/methods
Prostate-Specific Antigen*/blood
Prostatic Neoplasms*/blood
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/ethnology
Healthcare Disparities*
Humans ; Male ; American Indian or Alaska Native ; Primary Health Care ; Rectum ; White
Czasopismo naukowe
Szczegóły
Tytuł:
Impact of newly diagnosed prostate cancer at time of evaluation for renal transplantation.
Autorzy:
Poinard F; Department of Urology and Renal Transplantation, Georges Pompidou European Hospital, Paris, France.
Bessede T; Urology Department, Hopitaux Universitaires Paris-Sud, Le Kremlin-Bicetre, France.
Barrou B; Department of Urology and Renal Transplantation, APHP - Sorbonne University, Pitié Salpêtrière University Hospital, Paris, France.
Drouin S; Department of Urology and Renal Transplantation, APHP - Sorbonne University, Pitié Salpêtrière University Hospital, Paris, France.
Karam G; Department of Urology & Renal Transplantation, Hotel Dieu University Hospital, Nantes, France.
Branchereau J; Department of Urology & Renal Transplantation, Hotel Dieu University Hospital, Nantes, France.
Alezra E; Department of Urology, Bordeaux Pellegrin University Hospital, Bordeaux, France.
Thuret R; Department of Urology and Transplantation, Montpellier University Hospital, Montpellier, France.
Verhoest G; Department of Urology and Transplantation, Rennes University Hospital, Rennes, France.
Goujon A; Department of Urology and Transplantation, Rennes University Hospital, Rennes, France.
Millet C; Department of Urology, University of Clermont-Ferrand, Clermont-Ferrand, France.
Boissier R; Department of Urology & Renal Transplantation, La Conception University Hospital, Assistance-Publique Marseille, Aix-Marseille University, Marseille, France.
Delaporte V; Department of Urology & Renal Transplantation, La Conception University Hospital, Assistance-Publique Marseille, Aix-Marseille University, Marseille, France.
Sallusto F; Department of Urology, Kidney Transplantation and Andrology, Toulouse Rangueil University Hospital, Toulouse, France.
Prudhomme T; Department of Urology, Kidney Transplantation and Andrology, Toulouse Rangueil University Hospital, Toulouse, France.
Boutin JM; Department of Urology, Tours University Hospital, Tours, France.
Culty T; Department of Urology, Angers University Hospital, Angers, France.
Timsit MO; Department of Urology and Renal Transplantation, Georges Pompidou European Hospital, Paris, France.
Pokaż więcej
Źródło:
Clinical transplantation [Clin Transplant] 2023 Sep; Vol. 37 (9), pp. e14998. Date of Electronic Publication: 2023 May 03.
Typ publikacji:
Journal Article
MeSH Terms:
Kidney Transplantation*/adverse effects
Kidney Failure, Chronic*/diagnosis
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/epidemiology
Male ; Humans ; Retrospective Studies ; Waiting Lists
Czasopismo naukowe
Szczegóły
Tytuł:
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.
Autorzy:
Arafa AT; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Blader LR; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Ramakrishna K; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Engle J; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Ryan CJ; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.; Prostate Cancer Foundation, Santa Monica, California, USA.
Zorko NA; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Jha G; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Antonarakis ES; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Pokaż więcej
Źródło:
The Prostate [Prostate] 2023 Sep; Vol. 83 (13), pp. 1279-1284. Date of Electronic Publication: 2023 Jun 19.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms*/drug therapy
Androstenes*/therapeutic use
Androgen Antagonists*/therapeutic use
Humans ; Male ; Neoplasm Metastasis/pathology ; Retrospective Studies ; Case-Control Studies ; Progression-Free Survival ; Treatment Outcome
Czasopismo naukowe
Szczegóły
Tytuł:
Discovery of BWA-522 , a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.
Autorzy:
Zhang B; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Liu C; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Yang Z; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Zhang S; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
Hu X; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Li B; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Mao M; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Wang X; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
Li Z; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
Ma S; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
Zhang S; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
Qin C; Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.; Laboratory for Marine Drugs and Bioproducts, Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong 266137, China.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2023 Aug 24; Vol. 66 (16), pp. 11158-11186. Date of Electronic Publication: 2023 Aug 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Proteolysis Targeting Chimera*/chemistry
Proteolysis Targeting Chimera*/pharmacology
Animals ; Dogs ; Humans ; Male ; Mice ; Androgen Receptor Antagonists/pharmacology ; Androgen Receptor Antagonists/therapeutic use ; Androgen Receptor Antagonists/chemistry ; Cell Line, Tumor ; Cell Proliferation ; Receptors, Androgen/metabolism ; Ubiquitin-Protein Ligases
Czasopismo naukowe
Szczegóły
Tytuł:
ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer.
Autorzy:
Nie J; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China.
Zhang P; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China. Electronic address: .
Liang C; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China.
Yu Y; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China; Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China; Cancer Precision Diagnosis and Treatment and Translational Medicine, Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China. Electronic address: .
Wang X; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China; Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China; Cancer Precision Diagnosis and Treatment and Translational Medicine, Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China; Research Center of Wuhan for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, 430071, PR China. Electronic address: .
Pokaż więcej
Źródło:
Free radical biology & medicine [Free Radic Biol Med] 2023 Aug 20; Vol. 205, pp. 318-331. Date of Electronic Publication: 2023 Jun 22.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/genetics
Prostatic Neoplasms, Castration-Resistant*/pathology
Ferroptosis*/genetics
Prostatic Neoplasms*/metabolism
Male ; Humans ; Cell Differentiation ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Basic Helix-Loop-Helix Transcription Factors/genetics ; Basic Helix-Loop-Helix Transcription Factors/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Incidental Prostate Cancer: A 23-Year Review Of A Tertiary Care Hospital.
Autorzy:
Khalique A; Department of Urology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
Hussain M; Department of Urology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
Kumar P; Department of Urology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
Ali M; Department of Urology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
Hassan AS; Department of Urology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
Hashmi A; Department of Urology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
Pokaż więcej
Źródło:
JPMA. The Journal of the Pakistan Medical Association [J Pak Med Assoc] 2023 Aug; Vol. 73 (8), pp. 1709-1711.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neck Obstruction*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/epidemiology
Prostatic Neoplasms*/surgery
Neoplasms, Second Primary*
Male ; Humans ; Retrospective Studies ; Tertiary Care Centers ; Prostate/surgery
Czasopismo naukowe
Szczegóły
Tytuł:
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Autorzy:
Yanagisawa T; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan. .; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .
Kimura T; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Hata K; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.; Department of Urology, Atsugi City Hospital, Kanagawa, Japan.
Narita S; Department of Urology, Akita University School of Medicine, Akita, Japan.
Hatakeyama S; Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Mori K; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Sano T; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Otsuka T; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Iwamoto Y; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Enei Y; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Nakazono M; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Sakanaka K; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Iwatani K; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Matsukawa A; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Atsuta M; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Nishikawa H; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Tsuzuki S; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Miki J; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Habuchi T; Department of Urology, Akita University School of Medicine, Akita, Japan.
Ohyama C; Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Urology, Weill Cornell Medical College, New York, NY, USA.; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
Egawa S; Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan.
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2023 Aug; Vol. 41 (8), pp. 2051-2062. Date of Electronic Publication: 2022 May 21.
Typ publikacji:
Journal Article
MeSH Terms:
Prostatic Neoplasms*/pathology
Nonsteroidal Anti-Androgens*/therapeutic use
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Humans ; Docetaxel/therapeutic use ; Androgen Antagonists/therapeutic use ; Androgens/therapeutic use ; Retrospective Studies ; Propensity Score ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
Autorzy:
Freedland SJ; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; Section of Urology, Durham VA Medical Center, Durham, NC. Electronic address: .
Ramaswamy K; Pfizer, New York, NY.
Huang A; STATinMED Research, Plano, TX.
Sandin R; Pfizer AB, Sollentuna, Sweden.
Mardekian J; Pfizer, New York, NY.
Schultz NM; Astellas Pharma, Northbrook, IL.
Janjan N; STATinMED Research, Plano, TX.
George DJ; Duke Cancer Institute, University School of Medicine, Durham, NC.
Pokaż więcej
Źródło:
Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Aug; Vol. 21 (4), pp. 419-429. Date of Electronic Publication: 2023 Jan 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Prostatic Neoplasms, Castration-Resistant*/pathology
Prostatic Neoplasms*/drug therapy
Male ; Humans ; Prostate-Specific Antigen ; Retrospective Studies ; Androgen Antagonists/therapeutic use ; Proportional Hazards Models
Czasopismo naukowe
Szczegóły
Tytuł:
Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
Autorzy:
Jathal MK; Research Service, VA Northern California Health Care System, Mather, California, USA; Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA.
Siddiqui S; Research Service, VA Northern California Health Care System, Mather, California, USA.
Vasilatis DM; Research Service, VA Northern California Health Care System, Mather, California, USA; Department of Urologic Surgery, University of California Davis, Sacramento, California, USA.
Durbin Johnson BP; Division of Biostatistics, Department of Public Health Sciences, University of California Davis, Davis, California, USA.
Drake C; Department of Statistics, University of California Davis, Davis, California, USA.
Mooso BA; Research Service, VA Northern California Health Care System, Mather, California, USA.
D'Abronzo LS; Department of Urologic Surgery, University of California Davis, Sacramento, California, USA.
Batra N; Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California, USA.
Mudryj M; Research Service, VA Northern California Health Care System, Mather, California, USA; Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA.
Ghosh PM; Research Service, VA Northern California Health Care System, Mather, California, USA; Department of Urologic Surgery, University of California Davis, Sacramento, California, USA; Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California, USA. Electronic address: .
Pokaż więcej
Źródło:
The Journal of biological chemistry [J Biol Chem] 2023 Aug; Vol. 299 (8), pp. 104973. Date of Electronic Publication: 2023 Jun 26.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms, Castration-Resistant*/metabolism
Receptors, Androgen*/genetics
Receptors, Androgen*/metabolism
Humans ; Male ; Androgens/metabolism ; Cell Line, Tumor ; Ligands ; Neuregulin-1/genetics ; Receptor Protein-Tyrosine Kinases
Czasopismo naukowe
Szczegóły
Tytuł:
Current Management and Future Treatment Strategies for Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Autorzy:
Rajwa P; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. .; Department of Urology, Medical University of Silesia, 3 Maja Street 13-15, 41-800, Zabrze, Poland. .
Quhal F; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Tsaur I; Department and Outpatient Clinic for Urology and Pediatric Urology, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany.
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2023 Aug; Vol. 41 (8), pp. 2005-2006.
Typ publikacji:
Editorial
MeSH Terms:
Prostatic Neoplasms*/therapy
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Humans ; Hormones ; Androgen Antagonists/therapeutic use
Opinia redakcyjna
Szczegóły
Tytuł:
Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.
Autorzy:
Nierengarten MB
Pokaż więcej
Źródło:
Cancer [Cancer] 2023 Aug 01; Vol. 129 (15), pp. 2278.
Typ publikacji:
Wiadomości
MeSH Terms:
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Humans ; Nitriles ; Phenylthiohydantoin/therapeutic use ; Hormones ; Prostate-Specific Antigen
Periodyk
Szczegóły
Tytuł:
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Autorzy:
Armstrong AJ; Center for Prostate & Urologic Cancers, Duke Cancer Institute, Durham, NC, USA. Electronic address: .
Iguchi T; Kanazawa Medical University, Ishikawa, Japan.
Azad AA; Monash Health, Clayton, Victoria, Australia.
Villers A; University Hospital Centre, Lille University, Lille, France.
Alekseev B; Hertzen Moscow Cancer Research Institute, Moscow, Russia.
Petrylak DP; Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA.
Szmulewitz RZ; The University of Chicago, Chicago, IL, USA.
Alcaraz A; Hospital Clinic de Barcelona, Barcelona, Spain.
Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Holzbeierlein J; The University of Kansas Medical Center, Kansas City, KS, USA.
Gomez-Veiga F; Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
Rosbrook B; Pfizer Inc., San Diego, CA, USA.
Zohren F; Pfizer Inc., San Diego, CA, USA.
Haas GP; Astellas Pharma Inc., Northbrook, IL, USA.
Gourgiotti G; Department of Biostatistics, Oncology, Astellas Pharma Inc., London, UK.
El-Chaar N; Astellas Pharma Inc., Northbrook, IL, USA.
Stenzl A; Department of Urology, University Hospital, Eberhard Karls University of Tübingen, Tübingen, Germany.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2023 Aug; Vol. 84 (2), pp. 229-241. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Male ; Humans ; Androgen Antagonists/therapeutic use ; Androgens/therapeutic use ; Disease-Free Survival ; Treatment Outcome
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 80403

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies